Last reviewed · How we verify
OPL-002
At a glance
| Generic name | OPL-002 |
|---|---|
| Sponsor | Oppilan Pharma Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis (PHASE2)
- A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPL-002 CI brief — competitive landscape report
- OPL-002 updates RSS · CI watch RSS
- Oppilan Pharma Ltd portfolio CI